Nov 21, 2018, 7:00 am EST Synthetic Biologics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA on SYN-004 (ribaxamase) Development
Business Journals,
-- Single Phase 3 Clinical Trial May be Sufficient for Approval for Prevention of Antibiotic-Mediated Clostridium difficile…